JMP Securities Trims Viridian Therapeutics (NASDAQ:VRDN) Target Price to $38.00

Viridian Therapeutics (NASDAQ:VRDN – Free Report) had its price target trimmed by JMP Securities from $42.00 to $38.00 in a research note released on Tuesday, Benzinga reports. The brokerage currently has a market outperform rating on the stock. VRDN has been the topic of a number of other research reports. Wells Fargo & Company decreased […]

Leave a Reply

Your email address will not be published.

Previous post 2seventy bio (NASDAQ:TSVT) Earns “Outperform” Rating from Wedbush
Next post BioCardia (NASDAQ:BCDA) Given “Buy” Rating at HC Wainwright